
    study bay1128688/17472 (akrendo 1) was terminated early on 20 july 2018 due to hepatotoxicity
  
['endometriosis']
['bay1128688', 'placebo']

        Inclusion Criteria:

          -  Women of at least 18 years of age at the time of signing of informed consent

          -  Women with endometriosis confirmed by at least one of the two criteria:

               -  surgery within the last 10 years

               -  imaging within the last 12 months

          -  moderate to severe pelvic pain which will be assessed over a period of 28 days

          -  Willingness to use only ibuprofen as rescue pain medication for
             endometriosis-associated pelvic pain

          -  Willingness to use non-hormonal barrier method for contraception (here
             spermicide-coated condoms) from screening visit until the end of the study (unless
             adequate contraception is achieved by vasectomy of the partner or use of copper
             intrauterine device [IUD] or commitment to abstinence) and refrain from using hormonal
             contraception

        Exclusion Criteria:

          -  Pregnancy or lactation (more than three months since delivery, abortion, or lactation
             before start of treatment) AND no wish for pregnancy during the study

          -  Altered bilirubin metabolism and liver function at Visit 1

          -  Requirement to use pain medications for reasons other than endometriosis

          -  Contraindications to using ibuprofen

          -  Signs of hyperandrogenism

          -  Absence of menstrual cycles and/or abnormal vaginal/genital bleeding

          -  History of hysterectomy, tubal-ligation or bilateral ovariectomy

          -  Uncontrolled thyroid disorder
      